Document KGge8wg4QxkkmyNvzk7QgRjoQ
H f-r'f
31
000255
C-8 IN BLOED MONITORING RESULTS IN FLPR DORDRECHT
In past month o f May W opdsanmlesjyere taken o f 38 employees in the j p n Q Homo Polymers, F E P ^ jp fl^ p M Q M o n o m ers A-shift areas and some employees in the service areas. This as a part o f a c-8 in blood monitoring program in co-operation with DuPont FLPR Parkersburg and Dyneon in GendorfGermany. Dyneon is our partner in purifying the recovered c-8 and owner o f the technology. Previous c-8 in blood monitoring programs were conducted in 1997,1981, 1982 en 1984.
Introduction C-8 is dispergator, required for the manufacturing o f g H B p l o C-8 is a toxic substantive that can be inhaled and absorbed via skin contact. The c-
8 will be stored in the liver. C-8 is a toxic that should be discussed and registered in a yearly program with all
employees. In the list o f the Haskell lab, rev. July 1999, c-8 probably is no human carcinogen
and developmental toxic The exposure limit is 0,56 ppb. C-8 in the human body can be measured only by analyzing the blood. Up till now it was not possible to define a maximum exposure limit for c-8 in
blood.
The c-8 in blood samples were analyzed in two laboratories. All 38 samples were analyzed in the NMS labindeU .S . while 19 each ofthem were also analyzed in the Schiwara lab in Germany as cross checks. Tfie analyze results o f the two labs were corresponding pretty much. This makes that we have confidence in the results.
_ Characteristics o f the analyze results ^M M o n o m ers employees have lower c-8 levels. f l p B ^ ^ Iomopol^m ers^mployees have higher c-8 levels. a Q p B B ^ E P and ^ fl^em p lo y ees have c-8 levels intermediate o f both previous
areas. Compared with the 1997 c-8 in blood analyzing program, there was a relatively
slight difference in the c-8 levels o f employees that co-operated in both the 1997 and the 2000 program. In week 29 the Managers Operations had a personnel contact with the six employees with the highest c-8 in blood levels to discuss possible sources o f exposure and use o f PPE. These contacts helped to determine some unknown exposure sources.
On July 13 a team o f experts, Site physician, Site hygienist, FLPR c-8 coordinator, FLPR S&OH coordinator and Managers Operations, evaluated the results o f the analyzes. Appointments were made to present the results to the employees involved and to inform all other FLPR and DuPont Dow Elastomers J.V. employees by means o f an E-mail message.
Company Sanitized. Does not on*-'* tSCA CBf
000256
Conclusions There are considerable differences in c-8 levels between employees performing the
same jobs. An explanation for this phenomenon might be that the one person will pick up more c-8 and demolishes it slower than another persoa Give more attention to prevent skin exposure to c-8 and the use op proper PPE. Comparison o f the DDT c-8 analyzes with that o f PKB will be done later as the PKB results are not completed yet.
Path forward New samples to be taken from employees with high analyze results after two
years from now. o Further reduction o f risk sources. Make up an inventory o f the c-8 handling practices en use o f PPE, a Promotion o f awareness to prevent exposure for all employees. Give special attention for prevention o f exposure via the skin.
Sources for exposure High Pressure cleaning of Dispersion Poly kettles. All c-8 solved in water. All c-8 spills. PTFE Dispersions and non-dried Fine Powders. Coagulant and w astefrom the Wax trap. Supemate in ^ H M ^ io m o Polymers and Thermal Converter areas. Fine Powder Dryers, especially during dean-outs, a granular production line. p ^ ^ P E P Wet Finishing system. a Exhaust gasses and container changes in both c-8 recovery areas. Maintenance in c-8 containing equipment.
Actions taken to prevent exposure o C-8 solved in water instead o f c-8 powder in all areas. C-8 is injected automatically instead o f weighing and handling o f c-8 powder, o Air exhausts on wax separators. p Improve practices for cleaning o f Fine Powder Dryers, p Make up an inventory o f emission sources and adequate actions, p Proper procedures for use o f PPE. p Improvement o f c-8 recovery systems, o Communication with all employees.
Everybody's responsibility The exposure prevention by the properly use o f proper PPE, reporting o f risks for exposure and cooperation to accomplish improvements. This also being so Arholaw responsibility for all employees.
Company Sanitized. Does not contain TSGA CBI
000257
I FLPR DDT c-8 in blood 1997 vs 2000 sample results in ppb
5000
Nrs 1 t/m 15 zijn van 1997 prog.
8S2000
C ontrol it Sam ple ID
551474 1011.1 551475 1011.2
551476 1011.3
551477 1013.1 551478 1013.2 551473 1013.3
551480 1014.1
551481 1014.2 551482 10140 551483 1016.1
551484 10162: 551485 1016.3
551486 1012 551487 1017 561677 39-1980 561678 30-5155 561679 10-2935 561680 7-12493 561681 9-3789 561682 11-3240 561683 28-45566
561684 36-5165 561685 17-6063 561686 20-5669 561687 12-2180 561688 27-5868 561689 40-11825 561690 41-3952 561691 22-8215 561692 3-5251 561693 37-3145
561694 42-5883 561695 34-5523 561696 5-5978 561697 21-5421 561698 4-12933 561699 5-4588 561700 2-1530 561701 31-5652 561702 38-2378 561703 35-3405 561704 13-4791 561705 33-5474 561706 8-5742 561707 32-4507 561708 29-5504 56171 2545996 561710 15-4708 561711 16-3823 561712 23-6225 561713 26-5542 561714 19-4793
R ec'd Dati T est Name
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/98)0 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00
mm mm
PERFLUOROOCTANOIC ACID PERFLUOROOCTANOIC ACID PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00
mm
PERFLUOROOCTANOIC ACID PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00
mm mm mm mm
PERFLUOROOCTANOIC ACID PERFLUOROOCTANOIC ACID PERFLUOROOCTANOIC ACID PERFLUOROOCTANOIC ACID PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOIC ACID
6/9/00 PERFLUOROOCTANOICACID
6/9/00 PERFLUOROOCTANOICACID
R esult (ppb) Specim en Failed re-analysis Blood
Failed re-analysis Blood
Failed re-analysis Blood
Failed re-analysis Blood
Failed re-analysis Blood
Failed re-analysis Blood
Failed re-analysis Blood
7,200
Blood
10,000
Blood
150 Blood
7,600
Blood
13,000
Blood
42 Blood
115 Blood
98 Blood
230 Blood
1,100
Blood
950 Blood
4,500
Blood
2,000
Blood
270 Blood
330 Blood
1,400
Blood
1,000.
Blood
900 Blood
100 Blood
38 Blood
1,900
Blood
4,900
Blood
1,500
Blood
68 Blood
1,000
Blood
820 Blood
1,600
Blood
1,500
Blood
140 Blood
1,900
Blood
2,200
Blood
45 Blood
3,900
Blood
800 Blood
800 1,800
Blood Blood
1,200
Blood
1,500
Blood
180 Blood
1,300
Hood
4,500
Blood
10.000
Blood
1,500
Blood
670 Blood
8.900
Hood
A cct # 95240 95240 95240 95240 95240 95240
95240 95240 95240 95240 95240 95240
95240 95240 95240
95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240 95240
000259
CONFIDENTIAL
Analytical Results of PFOA blood samples
1
C om pany S am pling d a te
Dyneon
5/24/00
Dyneon
19.055000
Dyneon Dyneon Dyneon
19.05.2000 19.05.2000 19.055000
Dyneon D yneon
control + 5 mgfl control + 10 m g/t
Dyneon Dyneon Dyneon
18.055000 control +-5 m g/l control +10 mg/l
Dyneon
18.05.2000
Dyneon
18.055000
Dyneon
control+ 5 mg/l
Dyneon
control +10 mg/l
Dyneon Dyneon Dyneon Dyneon
18.055000 control + 5 mgfl control + 10 mg/l 17.05.2000
Dyneon Dyneon
D yneon
Dyneon
(\ D yneon
Dyneon D yneon
17.05.2000 17.055000 17.05.2000 16.05.2000 16.05.2000
16.05.2000 15.055000
Dyneon
15.055000
Dyneon
15.055000
D yneon
15.055000
DuPont DuPont DuPont DuPont DuPont DuPont DuPont DuPont DuPont DuPont DuPont DuPont DuPont DuPont D uPont DuPont DuPont DuPont DuPont
L abo r ID 1019 1018 1015 1017 1016 10162 10163 1014 10142 101 1011 1012 10122 16123 1013 10132 10133 1009 1010 1006 1007 1005 1004 1006 1003 1000 1001 1002
S chiw ant re s u lts m g/l
0.4 0.20 0.10 0.30 0.40 4.8 95 0.40 450 8.60 0.30 0.10 4.3 8.5 050 4 .4 8.8 1.00 0.10 0.20 0.20 050 0.60 0.30 0.10 0.30 0.10 aso
NM3 re s u lts m g/l
122180 163023 102935 85472 65970 412933 205669 229213 265542 285566 305155 324507 345523 365165 373145 382970 4011025 21530 425803
0.70 8.30
1.10 0.80 1.30 0.20 1.00 6.00 0.70 0.30 0.30 150 1.00 0.50 0.10 2.40 <0,1 2.30 0.80
0 0 2 0
XT
m # tzesvcT S
Y
JkOQO ! too.__ _..,,. 1*f&o._>_.. _. AffO .. _ ... A SoO T>\ oa ^0OO___ . 3Soo... ...... . tioo ..... |OOC 3oO a.too {OOO 33oo uoo 3-0O H7aC I3oo heQ A.SOO 36oo MSa
13.00 *J?oO ./flop........ 1300 lOCO . noo gSpo _ 3300__ 3SoO . ^oo /<too_
/3oo l/oo <^00 X opo
- - --...... --- ~ ---
- ------ -- -- -- ---- - -
____
&itv
Ftfilb*,
fP (42. re ^
r^ntz. Fr?/tt ftf'.f&S ? ..
P./63 ._ . .. ... .
CAM _ G.? ___
FpIt.S.
.PP. /fr*- _
..... ___ _____ _ ... ... ...____ .. ._... .... CA.O.H
*=*.*
000261
2000 C-8 BLOOD TESTING DISTRIBUTION OF RESULTS
PPB
0-999 1000-1999 2000 - 2999 3000-3999 4000 - 4999 5000-5999 6000-6999 7000 - 7999 8000 - 8999 9000 - 9999
NUMBER
87 16 ar 3 4 0 2 0 1 1
00262
^ < looo looo - i`
3 o op - .3 iM ii
^OOO5*000 i^O fto. 7o b o ^ o co - g'-gc?'? *?CO -
)
R edacted-Privacy
0 0 Z G 3
IIP !
000264
S92000 I
) 5
f
O. 0.038 1.
0<D>K4*) o>
T --<
.f Tn f. TVf
T ~ t _ r ~ t i T - t T ~ e Tu.f_T-.f T ^ r .TU*
F/M-----------flfflrf gflif...CflU -- J Z iL i.
F/M
Fep Fep Fep Fp Fep
31 39
15 32 33 34 35
FLPR DDT C-8 in blood May 2000 sample results
1.2 1
0.045 0.1
4.5 1.5 1,8 0.82 0.8
O
O
O
N <75 (75
92000
Fep Fep 36 42
0.S 0.8 0.33 1
Dag Dag Dag Dag Dag
4 13 16 37 40
0.2
8.3 0.1
0
0,14 0.8 10 0.038 0.038
FL.PR DDT c-8 in blood 1997 vs 2000 sample results in ppb
4500 4000 3500
Mulder Heer Boers 7 11 12
499 659 261 210
950 800
Nra 1 t/m 15 zijn van 1997 prog.
892000
